Your browser doesn't support javascript.
loading
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.
Peuker, Caroline A; Yaghobramzi, Sarvenaz; Grunert, Corinna; Keilholz, Luisa; Gjerga, Enio; Hennig, Steffen; Schaper, Sigrid; Na, Il-Kang; Keller, Ulrich; Brucker, Sara; Decker, Thomas; Fasching, Peter; Fehm, Tanja; Janni, Wolfgang; Kümmel, Sherko; Schneeweiss, Andreas; Schuler, Martin; Lüftner, Diana; Busse, Antonia.
Afiliação
  • Peuker CA; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Hindenburgdamm 30 Berlin, 12203, Germany.
  • Yaghobramzi S; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Hindenburgdamm 30 Berlin, 12203, Germany.
  • Grunert C; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Hindenburgdamm 30 Berlin, 12203, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin,
  • Keilholz L; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumor Immunology, Augustenburger Platz 1 Berlin, 13353, Germany.
  • Gjerga E; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Hindenburgdamm 30 Berlin, 12203, Germany.
  • Hennig S; HS Diagnomics GmbH, Berlin, Germany.
  • Schaper S; HS Diagnomics GmbH, Berlin, Germany.
  • Na IK; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumor Immunology, Augustenburger Platz 1 Berlin, 13353, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitépl
  • Keller U; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Hindenburgdamm 30 Berlin, 12203, Germany.
  • Brucker S; University of Tübingen, Department of Gynecology and Obstetrics, Tübingen, Germany.
  • Decker T; Clinic for Oncology Ravensburg, Ravensburg, Germany.
  • Fasching P; University Hospital Erlangen, Department of Gynecology and Obstetrics, Erlangen, Germany.
  • Fehm T; Heinrich Heine University Düsseldorf, Department of Gynecology and Obstetrics, Düsseldorf, Germany.
  • Janni W; University Hospital Ulm, Department of Gynecology and Obstetrics, Ulm, Germany.
  • Kümmel S; Kliniken Essen-Mitte, Breast Unit, Essen, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gynecology with Breast Center, Charitéplatz 1 Berlin, 10117, Germany.
  • Schneeweiss A; University Hospital and German Cancer Research Center, National Center for Tumor Diseases, Heidelberg, Germany.
  • Schuler M; University Hospital Essen, West German Cancer Center, Department of Medical Oncology, Essen, Germany; German Cancer Consortium (DKTK), Partner Site University Hospital Essen and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Lüftner D; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Hindenburgdamm 30 Berlin, 12203, Germany.
  • Busse A; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Hindenburgdamm 30 Berlin, 12203, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin,
Eur J Cancer ; 162: 45-55, 2022 02.
Article em En | MEDLINE | ID: mdl-34953442
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies Limite: Female / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies Limite: Female / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha